Suvretta Capital Management LLC Has $8.93 Million Position in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS)

Suvretta Capital Management LLC boosted its position in Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) by 32.8% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 5,073,913 shares of the biopharmaceutical company’s stock after buying an additional 1,253,901 shares during the quarter. Suvretta Capital Management LLC owned approximately 9.21% of Marinus Pharmaceuticals worth $8,930,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently bought and sold shares of the company. GSA Capital Partners LLP raised its holdings in shares of Marinus Pharmaceuticals by 409.4% in the third quarter. GSA Capital Partners LLP now owns 1,016,634 shares of the biopharmaceutical company’s stock valued at $1,789,000 after purchasing an additional 817,050 shares during the last quarter. abrdn plc increased its stake in Marinus Pharmaceuticals by 146.1% in the 3rd quarter. abrdn plc now owns 2,658,527 shares of the biopharmaceutical company’s stock valued at $4,679,000 after buying an additional 1,578,329 shares during the last quarter. Assenagon Asset Management S.A. lifted its position in Marinus Pharmaceuticals by 70.3% during the 3rd quarter. Assenagon Asset Management S.A. now owns 444,185 shares of the biopharmaceutical company’s stock worth $782,000 after buying an additional 183,396 shares in the last quarter. Point72 DIFC Ltd acquired a new position in shares of Marinus Pharmaceuticals during the 2nd quarter worth about $28,000. Finally, Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Marinus Pharmaceuticals in the 2nd quarter valued at about $64,000. Institutional investors own 98.80% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts recently issued reports on the company. Royal Bank of Canada dropped their target price on Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating on the stock in a report on Friday, October 25th. JMP Securities reiterated a “market perform” rating on shares of Marinus Pharmaceuticals in a research note on Thursday, October 24th. Jefferies Financial Group reissued a “hold” rating and issued a $0.50 target price (down from $5.00) on shares of Marinus Pharmaceuticals in a research note on Friday, October 25th. HC Wainwright reaffirmed a “neutral” rating and set a $2.00 price target on shares of Marinus Pharmaceuticals in a research report on Thursday, November 14th. Finally, StockNews.com initiated coverage on shares of Marinus Pharmaceuticals in a research report on Tuesday. They issued a “hold” rating for the company. Nine research analysts have rated the stock with a hold rating, two have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and a consensus price target of $4.79.

Marinus Pharmaceuticals Price Performance

Shares of MRNS stock opened at $0.32 on Friday. Marinus Pharmaceuticals, Inc. has a 52 week low of $0.26 and a 52 week high of $11.26. The company has a 50-day simple moving average of $1.01 and a 200 day simple moving average of $1.24.

Marinus Pharmaceuticals Profile

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.